ACCELERATING THE PACE OF DISCOVERY2013 Annual Report

MISSION Leading the fight to treat and cure ALS through global research and nationwide advocacy, while also empowering people

with Lou Gehrig’s Disease and their families to live fuller lives by providing them with compassionate care and support.

VISION Create a world without ALS

3

MESSAGE FROM JANE H. GILBERT

For those of us engaged in the fight against amyotrophic lateral sclerosis (ALS), nothing short of effective treat-ments and a cure will be considered a victory. The people who have been diagnosed, the families and friends who love and care for them and the millions who have already lost someone to ALS are looking to The ALS Association and the scientific community to lead the way in the quest to put an end to this terrible disease.

For decades, this journey has been slow and tedious; how- ever, reason for hope is on the horizon. Thanks to those who have partnered with and supported The ALS Association, there are many areas where encouraging progress indicates tangible results in the near future. As you will read in our financial report, The Association has been a good steward of your philanthropic contributions. This past year, 80 cents of every dollar you donated went to support programs serving the ALS community. Our ratios reflect an improved spending position thanks to more investment in research and realizing more than $6 million in donated media revenue—an area which will continue in future years, as we push forward to meet our goal of increased awareness for ALS.

Building on the discovery of the role of the C9orf72 gene mutation, which was published by two different ALS Association-funded research teams, many scientists across the globe have begun to explore new areas of ALS research. And, the focus on ALS Research during the past year has created unprecedented excitement among members of the scientific community.

The ALS Association’s nationwide network of chapters offer services to people with ALS and their families, and local certified centers and clinics provide multi-disciplinary care that is the recognized gold standard for treating ALS patients. A growing body of evidence indicates that this type of coordinated care not only helps people manage symptoms but may also increase life expectancy.

The Association’s public policy efforts have continued to successfully increase congressional support for ALS research funding at a time when many govern-ment programs have been reduced or eliminated. This achievement is due in great part to the active participation of advocates who come to Washington, D.C.,

each May during the National ALS Advocacy Day and Public Policy Conference. Advocates learn about the current initiatives and take their message to lawmakers on Capitol Hill. It is personal stories about living with the disease, along with a consistent, coordinated message that makes this approach so effective.

While ALS still must compete for public attention with causes that impact many more people, no disease is more devastating or deserving of public support. The Association was able to reach millions of Americans

through a successful public service announcement campaign, an invigorated public media outreach and the continually growing Walk to Defeat ALS® program. Altogether, the ALS message reached more people this year than ever before.

All of these successes, however, do not begin to address the depth and breadth of the need. People continue to be diagnosed. Families and their loved ones still suffer from the progressive nature of this disease. And the cruelest fact of all, every day more and more Americans die of ALS.

This is totally unacceptable to me personally and as President and CEO of The ALS Association. This is why I begin each day with a personal challenge: What can I do today to move us closer to finding answers? How can I help the nation become more involved in the fight to discover effective treatments? What leadership decisions can I make to guide The ALS Association toward our ultimate vision of creating a world without ALS?

With your support, I will continue to ask these questions, and to the best of my ability, work to provide smarter, faster, and more effective answers. This is my promise. This is my pledge. This is my purpose.

My most sincere thanks and very best regards,

Jane H. Gilbert President and Chief Executive Officer The ALS Association

4

The feeling that now is the time to capitalize on the growing understanding of the disease’s causes wasn’t lost on Capitol Hill. Just three days after people with ALS and their family members met with members of Congress at the National ALS Advocacy Day and Public Policy Conference, the U.S. House of Representatives passed legislation to provide $7.5 million in funding for the ALS Research Program at the Department of Defense––a 17 percent increase over the previous year, remarkable in an era of financial austerity. Meanwhile, from baseball stadiums to fundraising walks, and through television public service announcements and social media, more people than ever before were learn-ing about Lou Gehrig’s Disease. Many of them were joining robust local and national endeavors to assist people living with ALS and supporting the goal of bringing an end to the disease once and for all.

Driving these efforts, as has been the case since our founding in 1985, was The ALS Association––the only national nonprofit organization engaged in every aspect of the fight: coordinating and funding a global research program; advocating for policies and financial support to enhance the research effort and improve the lives of people living with ALS and their families; delivering state-of-the-art, multidisciplinary care through ALS Association Certified Centers of Excellence and clinics; providing education and resources to assist people with ALS and their families through their ordeal; and promoting awareness of and public support for Lou Gehrig’s Disease.

In FYE 2013, The Association gained steam in all of these areas––not the least of which was to fuel an ever-increasing pace of discovery that is moving us closer to a world without this devastating disease.

RESEARCH INVESTMENTS PAYING DIVIDENDS

The Association’s Translational Research Advancing Therapy for ALS TREAT ALS™ program serves as a catalyst for a systematic and comprehensive effort to solve the mysteries surrounding ALS and bring effective new treatments to people who urgently need them. It does so by funding a coordinated global research effort that helps to draw top researchers to the field and enables excit-ing new hypotheses to be pursued; by forging partnerships among researchers and with the government and private industry; and by hastening the pace at which promising laboratory discoveries can be translated into new therapies

IT’S BEEN MORE THAN SEVEN DECADES since amyotrophic lateral sclerosis (ALS) was first

brought to the public consciousness. On July 4, 1939, in one of the most famous speeches of

the 20th century, baseball great Lou Gehrig told a hushed Yankee Stadium crowd

about the illness that had ravaged his body, finally taking him out of the

Yankees’ lineup after a remarkable

2,130 consecutive games played.

At the time, few people knew anything about the progressive, degenerative neuro-

muscular disorder that takes hold of men and women, often in the prime of their lives, and steadily robs them of their ability to initiate and control muscle movement––and, eventually, to speak, eat or breathe. The average life expectancy from diagnosis is two to five years––and it was no different for Gehrig. Less than two years after he moved his fans to tears with his public farewell, the man whose strength and durability had earned him the nickname “Iron Horse” would lose his life to ALS, thereafter also known as

Lou Gehrig’s Disease.

For much of the time since Gehrig’s announcement, progress in the effort to defeat ALS––to understand its cause, develop effective treatments and ulti-mately find a cure––has been painfully slow. But in recent years, something has changed. Like never before, we are seeing an acceleration of the pace of discovery as scientists unravel the complex pathways involved in the develop-ment of ALS, learn about the genetic culprits, and follow these clues to develop promising new treatments to be tested in clinical trials. Lou Gehrig’s Disease continues to bring suffering to people from all walks of life––and immeasurable heartache to their spouses, children, parents, siblings and other loved ones. But it is now quite clear that the momentum is on the side of the growing community of researchers working to relegate ALS to the history books.

In FYE 2013, a coordinated worldwide ALS research effort made significant strides, taking advantage of major discoveries in genetics the year before and focusing attention on several key pathways as potential targets for treatment.

5

and moved through clinical trials. As of January 31, 2013, there were 97 active projects funded by The Association for a total commitment of more than $15.5 million. And by investing in a better understanding of the genetic and molecular causes of Lou Gehrig’s Disease, The Association is paving the way for exciting developments that are beginning to bear fruit. Capitalizing on Genetic Discoveries. One of the most closely watched develop-ments in ALS research in FYE 2013 stemmed from the discovery in late 2011 by two independent research teams that mu-tations in the C9orf72 gene are associated with ALS, as well as frontotemporal demen-tia (FTD). The announcement led to the recognition that the mutations in this gene are the single most common known cause of ALS throughout the world, accounting for approximately 35 percent of familial cases and six percent of sporadic (non-inherited) cases, as well as about one-fourth of FTD cases. Researchers funded by The Asso-ciation have led the way in characterizing the nature of the gene mutation, building the first cellular and animal models of the gene, and determining the consequences of the mutation for motor neurons and sur-rounding cells. A further understanding of how the mutated C9orf72 gene causes ALS will likely reveal important new path-ways that control motor neuron health and point to multiple targets for new drug therapies. In addition to fueling continued efforts to learn more about the gene’s role in Lou Gehrig’s Disease, The ALS Association is contributing to scientific dis-cussions on the topic. In October 2012, The Association presented a symposium at the annual meeting of the Society of Neuroscience––the largest gathering of neuroscientists in the world––on the latest understanding of the C9orf72 gene.

As researchers homed in on the C9orf72 gene, the biology of several other ALS genes was also the focus of important new discoveries. Similarly functioning

proteins produced by the genes FUS and TDP-43 have been linked to familial ALS and are believed to be involved in the disease, either by causing a new toxic response or through loss of the proteins’ normal function. ALS Association-funded researchers made a number of intriguing discoveries surrounding these proteins in FYE 2013. Among them was the observation that the FUS protein physically interacts with a protein called SMN, whose absence causes another motor neuron disease, spinal muscular atrophy. This interaction suggests that the two diseases may be linked at the cellular level. Other researchers funded

by The Association discovered that the FUS and TDP-43 proteins bind to some of the same genes, raising the likelihood that these genes may be especially important in understanding how mutations in FUS and TDP-43 cause ALS. Finally, ALS Associ-ation-funded researchers reported that a cell rescue strategy may go awry when TDP-43 is mutated, which could mean that removal of the enzyme at the heart of that strategy would be therapeutic.

Elsewhere, ALS Association-funded researchers showed that mutations in a transport gene called profilin appear to account for one to two percent of inherited ALS cases, highlighting the importance of the transport system within the cell for motor neuron health. Two ALS Association-

funded groups also made advances in understanding factors influencing the age of onset of ALS––discoveries that may lead to ways to delay onset by influencing these pathways.

Biomarkers Bring Valuable Tool to Clinical Trials. The effort to accelerate the process of taking promising drugs to clinical trials is advancing on multiple fronts. One involves the development of biomarkers––substances in the blood or cerebrospinal fluid that change with the disease state and thus can be used both for earlier diagnosis and the tracking of response to a therapy, facilitating

J. Paul Taylor, M.D., Ph.D., and Regina-Maria Kolaitis, Ph.D., 2012 recipient of The Milton Safenowitz Post-Doctoral Fellowship, from Saint Jude Children’s Research Hospital in Memphis, Tenn.

66

more decisive clinical trials of new drugs. The Association is funding a consortium effort, enlisting leading researchers and biotech companies in the search for reliable biomarkers of ALS. In FYE 2013, two laboratories funded by The Association announced their discoveries of potential biomarkers, which will now be refined and evaluated further for their potential to be used in clinical trials.

TREAT ALS Accelerates Development of New Therapies. The Association also continues to move proactively to speed therapy development combining efficient new drug discovery approaches with priorities set for existing drug

candidates to accelerate clinical testing of compounds with promise for the disease. In FYE 2013 more than $6.6 million was awarded by The Association through TREAT ALS in the form of grants, drug dis-covery contracts and clinical and research studies. Major funding was provided for the development of remote treatment strategies to aid home care of people with ALS, preclinical assessment of potential therapeutic compounds, biomarker development studies, and clini-cal pilot studies of new treatment strategies for ALS, in partnership with the Northeast ALS Consortium (NEALS) Clinical Trial Network. In March 2012, The Association brought together more than 120 researchers, drug developers, government officials, and other interested parties to brainstorm on ways to accelerate drug discovery for ALS treatment.

MAKING THE CASE: SUCCESSFUL ADVOCACY ON CAPITOL HILL

Every year in the nation’s capital, The ALS Association hosts the National ALS Advocacy Day and Public Policy Conference––a three-day event in which people touched by Lou Gehrig’s Disease from all walks of life and from nearly every state in the country gather to make their voices heard. At the 2012 con-ference held May 13 to 15, more than 900 attendees told the ALS story––their personal experiences and those of their loved ones––and urged legislators to support the needs of the ALS community.

One of the main goals was to urge Congress to step up the fight for a treat-ment and cure, and on that score the conference was a resounding success. Advocates held more than 400 meetings with members of Congress, and their compelling stories moved legislators to act swiftly. In addition to triggering the 17 percent increase in the ALS Research Program passed by the House of Representatives, the meetings led to a more than doubling of the number of co-sponsors of the Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network (MODDERN) Cures Act, legislation that would provide incentives to encourage the development of new treatments for diseases with unmet medical needs, including ALS. With bipartisan support, that legislation was introduced by Rep. Leonard Lance (R-NJ).

Public Policy Conference Offers Many Highlights. The conference was memorable in many ways. Dr. Kevin Horton, who leads the National ALS Registry at the Centers for Disease Control and Prevention, unveiled excit-ing new features of the registry, including modules that will collect additional information about the disease (such as information on head trauma) to help researchers find clues to the cause of ALS. Dr. Horton also announced the launching of a new tool that notifies people enrolled in the registry about clinical trials for which they may be eligible to participate. The conference featured the first-ever “familial ALS Summit” (fALS), where participants learned about exciting research into fALS and were able to share their personal experiences on issues unique to familial cases. At other sessions, renowned ALS researchers and representatives of the pharmaceutical and biotech industries discussed the latest advances in ALS research and the promising clinical trials underway.

7

National ALS Registry Brings Many Benefits. FYE 2013 was also notable for the continued support garnered for the National ALS Registry, which went live on October 19, 2010, and has the potential to become the single largest ALS research project ever created. The ALS Association led the successful fight to establish the registry and secure federal funding to design, build and implement it at the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry. The registry’s aim is to identify ALS cases throughout the United States––every person in the country living with Lou Gehrig’s Disease can self-enroll––and, more importantly, to collect critical information about the disease that will improve care, reveal insights into its causes, and point researchers toward potential treatment and prevention strategies.

In FYE 2013, The Association worked with Reps. Eliot Engel (D-NY) and Peter King (R-NY) to circulate a “Dear Colleague” letter among members of Congress to ensure continued funding for the registry. More than 45 members signed the letter, which was delivered to the House Appropriations Committee. In the Senate, the Appropriations Committee voted to provide an additional $6 million to continue the registry. The legislation ultimately passed, bringing total registry funding to more than $30 million.

Research Funding Increases. Meanwhile, the increase for the ALS Research Program at the Department of Defense to $7.5 million brings the total funding for the program to $40 million, all of which is explicitly focused on finding treat-ments for ALS. The vote came after The Association worked with Reps. Elton Gallegly (R-CA) and Chellie Pingree (D-ME) to circulate a “Dear Colleague” letter in the House, which was signed by 55 members of Congress.

FDA Policies Aim to Accelerate Drug Approval Process. The Association also worked with the U.S. Food and Drug Administration in FYE 2013 to enact two important policies aiming to expedite the development and approval of ALS treatments. The Food and Drug Administration Safety and Innovation Act, signed into law on July 9, 2012, and the Prescription Drug User Fee Act, renewed for the fifth time in 2012, include important provisions that, among other things, strengthen the fast-track and accelerated approval processes to speed access to new treatments; require the FDA to partner more closely with patient organizations representing those with rare diseases; and provide addi-tional flexibility for the FDA to approve new treatments more quickly through the use of biomarkers and other surrogate endpoints.

ENSURING STATE-OF-THE-ART CARE AND SUPPORT

While leaving no stone unturned in the pursuit of better treatments and a cure for Lou Gehrig’s Disease, The ALS Association is equally focused on ensuring excellent care and support for the people who are currently living with ALS, as well as for the family members who are going through the ordeal with them. The Association’s nation-wide network of chapters and other partners provide local patient and family support in communities across the country. Each chapter is a grass-roots organization that carries out The Association’s mis-sion and strategic goals at the community level.

With support from the national office, chapters provide a wide range of services for people living with ALS, their caregivers, families and friends, along with professional health care providers throughout the service area. This includes patient education programs, support groups and referral services, as well as equipment loan programs, augmentative communication device programs, and referrals to ALS clinics and physicians. In addition, The ALS Association’s Certified Center program defines, establishes and supports a national standard of care in the management of ALS, including multidisciplinary, state-of-the-art care and services in a supportive atmosphere that emphasizes hope and quality of life. The Association supports 34 Certified Centers of Excellence as well as 42 non-certified clinics providing services that follow nationally established “best practice” standards of care.

As part of The Association’s continued effort to ensure the most effective care for ALS patients, a cost study was initiated using data collected through 18 of The Association’s Certified Centers. The goal: to identify specific costs associ-ated with providing care through a clinical center of excellence. An additional

8

case study of one family’s financial journey was completed on a retrospective basis. Results from each of these studies were presented at the ALS/MND International Symposium in December 2012.

A Wide-Ranging Educational Curriculum. Recognizing the importance of edu-cation for providers, staff, people living with the disease, families and caregivers, The Association has developed an education curriculum that includes meetings for medical directors, a national clinical conference, regional meetings, assistive technology and professional topic webinars, research updates, sessions at the National ALS Advocacy Day and Public Policy Conference, and a library of more than 50 published documents. The national office handles more than 400 information requests and referral programs per month.

Meanwhile, The Association continues to work with chapters and providers to identify opportunities and models of service delivery that will expand access to The Association’s services and programs, while achieving consistency in our portfolio across the country. Recognizing the value of collaboration, The Association also continues to reach out to other organizations in an effort to increase effectiveness and efficiencies.

SPREADING THE WORD AND ENLISTING NEW MEMBERS TO THE CAUSE

For the thousands who are affected by Lou Gehrig’s Disease now and in the future, having a reliable information source as well as open lines of communi-cation with both experts and others experiencing the same struggles is vitally important. Moreover, while people with ALS and their loved ones know all too well about the havoc wreaked by ALS, tens of millions of Americans who haven’t been personally affected must be made aware of the urgency to overcome this terrible disease.

Website Enhances Visibility. The Association works on all of these fronts to improve awareness of Lou Gehrig’s Disease, starting with our website (www.alsa.org). In FYE 2013, many improvements were made to the site to keep it fresh and enhance the visitor experience. These included greater visibility for stories published by The Association, links to general news stories about ALS, a reorganized front-page navigation, and an embedded Twitter feed. The reorganization also provides a more direct path for users to take action,

with a one-click “donate now” button highlighted, as well as larger links reading: “Advocate” and “Help Fight ALS.” These improvements have contrib-uted to a significant increase in traffic on the page, with the average monthly unique-visitor rate growing by 100,000 over the previous year. Overall, traffic to the site is well above benchmarks for disease and health charities and has recently begun to exceed the benchmark for the largest nonprofits.

Social Media Outlets Help to Increase Interaction. Social media also contin-ues to play an increasingly important role as a vehicle for sharing information and interacting with families fighting ALS, as well as with the general public. The Association utilizes several social media channels, including Facebook, Twitter, LinkedIn, Google+ and Pinterest, sharing information about its research and care services programs, public policy endeavors, and awareness activities. In FYE 2013, for the first time The Association live-streamed Advocacy Day conference sessions on our Facebook page for conference non-attendees. For the year, Facebook “likes” increased by more than 25 percent, while Twitter followers grew by 40 percent. In an effort to help people with ALS enroll in the National ALS Registry, The Association engaged in a number of public aware-ness activities, including a national awareness campaign with Minor League Baseball and a nationwide ALS Registry public service announcement featuring baseball great Tommy John.

Outreach to Traditional Media Keeps ALS in Public Eye. Enhancing aware-ness is also accomplished through traditional media. Partly due to a more robust media outreach effort and an increase in the number and frequency of ALS research study publications, The Association experienced a 39 percent increase in media mentions in FYE 2013 compared with the previous year. The Association held its annual Veterans Day letter-to-the-editor campaign, and staff participated in interviews for newspaper articles and talk-radio programs. Particularly notable was a television public service announcement (PSA) produced by The Association with TV and Broadway star Jason Alexander and Steve Posso, who has lived with ALS since 2007. The PSA debuted in January 2012 and soon was appearing on network, regional and cable TV stations nationwide, airing nearly 18,000 times on more than 140 stations to a viewing audience of 408 million for the year, as well as being shown in movie theaters across the country. This effort amounted to more than $6 million in donated, in-kind advertising revenue.

9

Walk to Defeat ALS® Marches On. Finally, there was the Walk to Defeat ALS, a nationwide cam-paign to bring hope to people with the disease while raising money for a cure through high-profile events. FYE 2013 represented a new milestone for the program, with 170 walks and approximately 175,000 walkers raising $21.7 million––a six per-cent increase over the previous year. Since 2000, the Walk to Defeat ALS has contributed more than $159 million toward the fight to bring an end to the disease.

FIGHTING FOR THOSE WHO CAN’T

Lou Gehrig’s Disease robs individuals of their physical capabilities. It can be extremely trying not only for people with the disease, but also for

family members who must stand by as their loved ones deteriorate, powerless to prevent the decline. But through the efforts of The ALS Association, these individuals will never feel alone. Indeed, they are not alone. They are joined by the legions of community members all over the country, enlisted to the cause and walking in solidarity with those who can no longer do so. The Association is fighting for all of these individuals. And as we continue our march toward a world without ALS, our pace is accelerating.

10

CONTENTS

INDEPENDENT AUDITORS’ REPORT 11

STATEMENT OF FINANCIAL POSITION 12

STATEMENT OF ACTIVITIES 13

STATEMENT OF FUNCTIONAL EXPENSES 14

STATEMENT OF CASH FLOWS 15

NOTES TO THE FINANCIAL STATEMENTS 16-20

11

Report on the Financial Statements

We have audited the accompanying financial statements of The Amyotrophic Lateral Sclerosis Association (The “Association”) which comprise the statement of financial position as of January 31, 2013, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, imple- mentation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards appli-cable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial state-ments in order to design audit procedures that are appropriate in the circum-stances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by manage-ment, as well as evaluating the overall presentation of the financial statements.

INDEPENDENT AUDITORS’ REPORT

The Board of TrusteesThe Amyotrophic Lateral Sclerosis Association

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of The Association at January 31, 2013, and the changes in its net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Report on Summarized Comparative Information

We have previously audited The Amyotrophic Lateral Sclerosis Association’s 2012 financial statements, and our report dated May 17, 2012, expressed an unmodified opinion on those audited financial statements. In our opinion, the summarized comparative information presented herein as of and for the year ended January 31, 2012, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we have also issued our report dated June 18, 2013, on our consideration of The Amyotrophic Lateral Sclerosis Association’s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compli-ance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering The Amyotrophic Lateral Sclerosis Association’s internal control over financial reporting and compliance.

Long Beach, CaliforniaJune 18, 2013

12

STATEMENT OF FINANCIAL POSITION FOR THE FISCAL YEAR ENDED JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

JANUARY 31, 2013 2012

ASSETS

9

Cash and cash equivalents $ 7,302,712 $ 6,834,970Investments in marketable securities 7,314,287 6,724,420Receivables: Bequests, net 333,604 731,231 Chapters, net 2,695,876 3,724,841 Pledges, net 696,219 321,402 Other 38,105 174,318Prepaid expenses 230,418 305,027

Beneficial interest in perpetual trusts 970,275 939,667

Contributions receivable from remainder trusts 207,483 291,389

Property and equipment, net 222,142 165,883

Other assets 48,848 43,191

TOTAL ASSETS $ 20,059,969 $ 20,256,339

LIABILITIES AND NET ASSETSLIABILITIES

Grants payable $ 180,334 453,556

Accounts payable and accrued expenses 1,345,713 1,167,003Annuity payment liability 788,970 754,538

Deferred rent 242,758 385,859

Total liabilities $ 2,557,775 2,760,956

COMMITMENTS (Note 6)

NET ASSETS

Unrestricted 8,317,870 8,106,576

Temporarily restricted 8,260,444 8,492,325

Permanently restricted 923,880 896,482

Total net assets 17,502,194 17,495,383

TOTAL LIABILITIES AND NET ASSETS $ 20,059,969 $ 20,256,339

See Independent Auditors’ Report. The accompanying notes are an integral part of these financial statements.

ASSETS

13

STATEMENT OF ACTIVITIES FOR THE FISCAL YEAR ENDED JANUARY 31, 2013, WITH COMPARATIVE TOTALS

TOTAL 2013 2012

SUPPORT AND REVENUE

Contributions $ 5,960,075 $ 2,377,873 $ 8,337,948 $ 7,177,133

Bequests 2,108,599 486,027 2,594,626 3,222,798

Chapters 4,470,652 3,256,773 7,727,425 7,572,676

In-kind public service announcements 6,030,011 6,030,011

Events, net of expenses 317,220 317,220 725,631

Federated campaigns 327,865 327,865 334,174

Investment income 298,915 73,633 372,548 99,175

Other income 87,411 87,411 54,211

Gain on beneficial interest in perpetual trusts $ 27,398 27,398 29,180

Change in value of split-interest agreements ( 77,940) ( 77,940) ( 172,401)

19,600,748 6,116,366 27,398 25,744,512 19,042,577

Net assets released from restrictions 6,348,247 ( 6,348,247)

Total support and revenue 25,948,995 ( 231,881) 27,398 25,744,512 19,042,577

EXPENSES

Research grants 6,616,367 6,616,367 3,904,240

Patient and community services 5,046,087 5,046,087 4,629,111

Public and professional education 8,878,559 8,878,559 1,859,100

Fundraising 3,000,946 3,000,946 3,269,624

Administration 2,195,742 2,195,742 1,773,152

Total expenses 25,737,701 25,737,701 15,435,227

CHANGE IN NET ASSETS 211,294 ( 231,881) 27,398 6,811 3,607,350

NET ASSETS–

Beginning of year 8,106,576 8,492,325 896,482 17,495,383 13,888,033

NET ASSETS–

End of year $ 8,317,870 8,260,444 $ 923,880 $ 17,502,194 $ 17,495,383

UNRESTRICTEDTEMPORARILYRESTRICTED

PERMANENTLYRESTRICTED

See Independent Auditors’ Report. The accompanying notes are an integral part of these financial statements.

14

STATEMENT OF FUNCTIONAL EXPENSES JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

PROGRAM ACTIVITIES SUPPORTING ACTIVITIES TOTAL EXPENSES

PATIENT AND PUBLIC AND RESEARCH COMMUNITY PROFESSIONAL GRANTS SERVICES EDUCATION TOTAL FUNDRAISING ADMINISTRATION TOTAL 2013 2012

EXPENSES Grant awards $ 5,993,945 $ 766,429 $ 20,000 $ 6,780,374 $ 6,780,374 $ 4,043,582

Chapter support 1,005,327 1,005,327 1,005,327 760,579

Salaries and related expenses 33,524 2,015,958 1,019,820 3,069,302 1,060,700 $ 1,008,715 2,069,415 5,138,717 4,865,099

Printing, publications and

public service announcements 7 143,898 197,361 341,266 104,343 3,683 108,026 449,291 427,479

In-kind public service announcements 6,030,011 6,030,011 6,030,011

Professional fees and

contract services 273,280 495,597 899,297 1,668,174 1,498,934 305,839 1,804,773 3,472,947 2,898,877

Postage and shipping 5 15,618 24,954 40,577 88,858 11,888 100,746 141,323 121,350

Rent and occupancy 143,943 93,228 237,171 90,628 158,134 248,762 485,933 784,787

Travel and conferences 305,974 327,297 435,972 1,069,243 51,341 50,591 101,932 1,171,175 990,212

Telecommunications 9,191 50,339 41,281 100,811 27,741 37,368 65,109 165,920 154,065

Office supplies 21 12,716 59,022 71,759 3,899 9,848 13,747 85,506 35,309

Dues and subscriptions 420 17,895 42,831 61,146 13,970 41,634 55,604 116,750 108,838

Bad-debt expense (recoveries) 268,146 268,146 268,146 ( 75,200)

Depreciation 38,799 8,195 46,994 13,560 24,570 38,130 85,124 153,243

Miscellaneous 12,271 6,587 18,858 46,972 275,326 322,298 341,156 167,007

2013 TOTALS $ 6,616,367 $ 5,046,087 $ 8,878,559 $ 20,541,013 $ 3,000,946 $ 2,195,742 $ 5,196,688 25,737,701

2012 TOTALS $ 3,904,240 $ 4,629,111 $ 1,859,100 $ 10,392,451 $ 3,269,624 $ 1,773,152 $ 5,042,776 $ 15,435,227

PERCENTAGE OF TOTAL EXPENSES

2013 25.7% 19.6% 34.5% 79.8% 11.7% 8.5% 20.2% 100.0%

2012 25.3% 30.0% 12.0% 67.3% 21.2% 11.5% 32.7% 100.0%

See Independent Auditors’ Report. The accompanying notes are an integral part of these financial statements.

15

STATEMENT OF CASH FLOWS JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

CASH FLOWS FROM OPERATING ACTIVITIES

Change in net assets $ 6,811 $ 3,607,350 Adjustments to reconcile change in net assets to net cash flows from operating activities: Depreciation 76,007 153,243 Realized/unrealized (gain) loss on investments ( 209,576) 20,792 Disposal of equipment 4,181 Noncash contributions to investments ( 63,879) ( 33,158)

Change in beneficial interest in perpetual trusts ( 30,608) ( 311,998)

Change in value of charitable remainder trusts 83,906 12,404 Changes in operating assets and liabilities: Receivables: Bequests net 397,627 590,524 Chapters, net 1,028,965 ( 910,388) Pledges, net ( 374,817) 177,143 Other 136,213 ( 150,155) Prepaid expenses 74,609 ( 146,381) Other assets ( 5,657) Grants payable ( 273,222) ( 892,329) Accounts payable and accrued expenses 178,710 ( 580,640) Annuity payment liability 34,432 142,607

Deferred rent ( 143,101) 236,956

Net Cash Provided by Operating Activities 920,601 1,915,970

CASH FLOWS FROM INVESTING ACTIVITIES

Proceeds from sold and matured investments 1,534,182 2,193,407

Purchases of investments ( 1,850,594) ( 6,574,785)

Purchases of property and equipment ( 136,447) ( 40,098)

Net Cash Used In Investing Activities ( 452,859) ( 4,421,476)

NET CHANGE IN CASH AND CASH EQUIVALENTS 467,742 ( 2,505,506)

CASH AND CASH EQUIVALENTS–Beginning of year 6,834,970 9,340,476

CASH AND CASH EQUIVALENTS–End of year $ 7,302,712 $ 6,834,970

FROM YEAR ENDED JANUARY 31, 2013 2012

See Independent Auditors’ Report. The accompanying notes are an integral part of these financial statements.

TOTAL COMBINED REVENUE $64,661,521

TOTAL COMBINED EXPENSES

Research $ 6,616,367

Other program activities 40,164,177

Fundraising 9,137,186

General & administration $ 5,414,990

Total expenses $61,332,720

Change in net assets: $3,328,800

The consolidated summary has not been audited or reviewed by the auditors and is not part of their financial reports.

CONSOLIDATED FINANCIAL SUMMARY,NATIONAL OFFICE AND CHAPTERSFOR THE YEAR ENDED JANUARY 31, 2013

16

THE ASSOCIATION The Amyotrophic Lateral Sclerosis Association (The Association) was organized in 1985 through the merger of its predecessors, The Amyotrophic Lateral Sclerosis Society of America and The National ALS Foundation, Inc. The Association’s principal purpose is to fund research directed at finding the cause and cure for the disease amyotrophic lateral sclerosis (ALS), commonly known as “Lou Gehrig’s Disease,” and to provide educational and other services to patients and their families, health care professionals, legislators, and local communities, principally through the dissemination of informative literature and presentation of public awareness and advocacy programs and scientific symposiums and by accrediting, with local chapter support, activities of patient care clinics known as ALS Association Centers.

The Association is a not-for-profit, voluntary health organization, exempt, together with its affiliated chapters, from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (the Code). The ALS Association and its chapters are classi-fied collectively as a publicly supported charitable organization under Section 509(a)(1) and qualify for the maximum charitable contribution deduction by donors under Section 170 (b)(1)(A)(vi) of the Code.

These financial statements do not include the accounts of affiliated chapters since, subject to their agreements with The Association, they are inde-pendently controlled by their own governing boards.

BASIS OF PRESENTATION The accompanying financial statements include a statement of financial position that presents the amounts for each of three classes of net assets–– unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets––based on the existence or absence of donor-imposed restrictions, a statement of activities that reflects the changes in those categories of net assets, and a statement of functional expenses that associates expenses with service efforts.

Unrestricted net assets include those net assets that may be used by The Association for any of its programs or administrative support. Temporarily restricted net assets include those net assets whose use by The Association has been limited by donors to specified purposes or time restrictions. Permanently restricted net assets include those net assets that must be maintained in perpetuity.

PRIOR-PERIOD INFORMATION The financial statements include certain prior-year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in con-formity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with The Association’s financial statements for the year ended January 31, 2012, from which the summarized infor-mation was derived.

USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS Cash equivalents are defined as money market funds and other highly liquid investments with original ma-turities of three months or less at the date they are purchased.

INVESTMENTS IN MARKETABLE SECURITIES Investments are initially recorded at cost if pur-chased, or at fair value at the date of donation if contributed. Subsequent to acquisition, investments are reported at their fair value. Investment income and realized and unrealized gains and losses are recognized as unrestricted net assets unless their use is temporarily or permanently restricted by donors to a specified purpose or future period. The fair value of investments in securities traded on a national securi-ties exchange are valued at the closing price on the last business day of the fiscal year, whereas securities traded on the over-the-counter market are valued at the last reported bid price.

NOTE 1–Description of Operations and Summary of Accounting Policies

NOTES TO THE FINANCIAL STATEMENTS JANUARY 31, 2013, WITH COMPARATIVE TOTALS FOR 2012

FINANCIAL RISK The Association maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Association places its cash with high quality financial institutions and has not experienced any losses in such accounts.

The Association’s investments are exposed to vari-ous risks, such as market and credit risks. Due to the level of risk associated with such investments and the level of uncertainty related to changes in the value of such investments, it is at least reasonably possible that changes in risks in the near term could materially affect investment balances and the amounts reported in the financial statements.

CONTRIBUTIONS AND BEQUESTS Contributions, including endowment gifts and pledg-es, are recognized as support in the period received or pledged. Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their esti-mated future cash flows. Amortization of the discount to present value is included in contribution revenue. Conditional promises to give are not included as support until the conditions are substantially met.

Bequests are recognized at the time The Associa-tion’s right to them is established by a court and the proceeds are subject to reasonable estimation.

Donations and bequests received with donor stipu-lations as to their intended use are reported in the statement of activities as restricted support. Tempo-rarily restricted net assets are reclassified as unre-stricted net assets when restrictions are met.

Contributed services are reported at fair value in the financial statements for voluntary donations of services when those services (1) create or enhance nonfinancial assets or (2) require specialized skills provided by individuals possessing those skills and are services which would be typically purchased if not provided by donation. The Association receives a substantial number of volunteer hours donated by individuals in program services and fundraising cam-paigns which are not recorded in the financial state-ments. Donated materials are recorded at their fair value at the date of the gift. If donors stipulate how long donated assets must be used, the contributions are recorded as restricted support. In the absence of such stipulations, contributions of goods are recorded as unrestricted support.

Beneficial interests in perpetual trusts are recognized as revenue when The Association is notified of the trust’s existence in accordance with the terms and provisions of the trust. The fair value of the contribu-tion is estimated using the fair value of the assets con-tributed to the trust, unless facts and circumstances indicate that the fair value of the beneficial interest differs from the fair value of the assets contributed to the trust. The contribution is classified as temporarily or permanently restricted support, depending on the nature of donor restriction, and annual distributions from the trust are reported as investment income that increases unrestricted net assets. At each report-ing date, the beneficial interest is remeasured at fair value using the same valuation technique that was used to measure the asset initially and the change in fair value is recognized as temporarily or permanently restricted gains or losses.

The Association is the beneficiary of two charitable remainder trusts for which The Association is not the trustee. The Association recognizes the present value of the estimated future benefits to be received

when the trust assets are distributed as temporarily restricted contribution revenue and as a receivable. Adjustments to the receivable to reflect amortization of the discount and revaluation of the present value of the estimated future payments to the lifetime ben-eficiary are recognized in the statement of activities as change in value of split-interest agreements.

IN-KIND CONTRIBUTIONS The Association produces and distributes public ser-vice television announcements that focus attention on education and awareness. These public service announcements are distributed to media stations nationwide and run free of charge. The Association has contracted with an independent outside agency to track the date and time that each public service announcement runs, and the value of the announce-ments is based on the date, time and market. For the year ended January 31, 2013, The Association recorded $6,030,011 of contributed public service announcements.

CHAPTER SUPPORT The Association has a revenue-sharing practice with affiliated chapters. Chapter support is recognized as support revenue when earned by the affiliated chapter based on the current revenue-sharing plan.

From time to time, The Association may provide loans for working capital needs to affiliated chap-ters. Generally, repayment of the loan begins one year from the date of the last loan installment. In the current year, The Association entered into three zero-interest twenty-year loans with three affiliated chapters. These loans to affiliated chapters are discounted at three percent based on the long-term Applicable Federal Rate (AFR), which is what the IRS would use to determine the unstated interest rate.

NOTE 1–Description of Operations and Summary of Accounting Policies– CONT.

17

18

PROPERTY AND EQUIPMENT Expenditures for property and equipment are capitalized at cost or, for donated assets, fair value at the time of donation. Depreciation and amortization is provided on a straight-line basis over the estimated useful lives of the related assets, ranging from three to five years.

RESEARCH GRANT EXPENSE Conditional research grants (see Note 6) are expensed by The Association as the researchers substantially meet the terms and conditions of the grant during the grant period. Unconditional research grants are expensed when made.

FUNCTIONAL EXPENSES The costs of providing various programs and activi-ties of The Association have been summarized on a functional basis in the statements of activities and functional expenses. The majority of expenses are directly identified with a program, activity or support-ing service and allocated accordingly. Expenses not directly identified are allocated among programs, activities and supporting services based on the judgment of management.

ALLOCATION OF JOINT COSTS The Association incurred joint costs for informational mailings that included fundraising appeals. The Association is permitted through accounting guid-ance to allocate to its programs a portion of its costs associated with its fundraising efforts. Costs are allocated between program and fundraising based on the percentage of words used for each purpose in a mailing. For the year ended January 31, 2013, joint costs totaled $767,012 and $238,468 for fundraising and program services, respectively.

INCOME TAXES The Association is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) and state taxes related to revenue received in connection with exempt programs. The Association recognizes the financial statement benefit of tax positions, such as its filing status as tax-exempt, only after determin-ing that the relevant tax authority would more likely than not sustain the position following an audit. The Association is subject to potential income tax audits on open tax years by any taxing jurisdiction in which it operates. The statute of limitations for federal purposes is three years and for state purposes is generally three to four years.

SUBSEQUENT EVENTS The Association has evaluated subsequent events and transactions for potential recognition or disclosure through June 18, 2013, the date financial statements were available to be issued.

Investments in marketable securities consist of the following:

NOTE 2–Investments in Marketable Securities–CONT.

Investments income consists of the following:

Interest income $ 162,972 $ 119,967Realized/unrealized 209,576 ( 20,792 ) gain (loss) $ 372,548 $ 99,175

NOTE 1–Description of Operations and Summary of Accounting Policies–CONT.

Mutual funds $ 3,267,077 $ 2,955,154Equity securities 1,930,040 1,697,326 Corporate bonds 1,113,379 1,070,521Government agency obligations 675,348 619,883 Government backed 134,734 175,362 mortgage securitiesCorporate mortgage securities 193,709 172,013 Others 34,161

$ 7,314,287 $ 6,724,420

JANUARY 31, 2013 2012

FOR THE YEAR ENDED JANUARY 31, 2013 2012

NOTE 2–Investments in Marketable Securities

Receivables from Chapters consist of the following:

NOTE 3–Chapter Receivables

JANUARY 31, 2013 2012

Revenue sharing $ 1,864,382 $ 3,308,665 Reserve for ( 123,436 ) ( 365,435 ) 1,740,946 2,943,230 Loans receivable 1,182,910 781,611Discount to ( 227,980 ) 954,930 781,611

$ 2,695,876 $ 3,724,841

doubtful collection

present value

1919

2014 $ 4,763,812 2015 1,482,2292016 464,149 $ 6,710,190

The Association anticipates collection of outstanding pledges receivable as follows:

Gross amounts due in: Less than one year $ 549,363 $ 273,888 One to five years 238,025 203,700 More than five years 15,000 15,000 802,388 492,588Less discount to ( 19,948) ( 24,011 ) present valueLess reserve for ( 86,221) ( 147,175 ) uncollectible pledges $ 696,219 $ 321,402

Amounts presented above have been discounted to present value using rates ranging from 1.54% to 4.75%.

RESEARCH GRANTS The Association enters into conditional commitments semiannually to award scientific research grants. Research grants are awarded after review by The Association’s Scientific Review Committee and approval by the Board of Trustees. Subject to an annual review and reapproval process, these grants generally cover a period of one to three years.

Subject to the grantees’ meeting the applicable terms and conditions timely, conditional grants awarded to date will become payable as follows:

Property and equipment consists of the following:

Except as previously provided for by restricted gifts (see Note 7),The Association’s ability to meet these grant commitments may be dependent on future contributions to be received.

LEASES The Association leases offices in California, Illinois, New Hampshire and Washington, D.C., under non-cancellable operating leases expiring November 2015 and June 2020, respectively. The leases require monthly rental payments and contain certain escalation clauses. In addition,The Association pays a pro-rata share of real estate taxes and other operating expenses.

The Association also leases certain office equipment under leases expiring at various dates through January 2017.

2014 $ 520,544 2015 646,7482016 605,9652017 321,7882018 330,638Thereafter 806,208

$ 3,231,891

Rent expense under office and equipment leases amounted to $524,562 and $784,787 for the years ended January 31, 2013 and 2012, respectively.

In January 2013, The Association entered into a sublease agreement with a Chapter which termi-nates November 2015. The Association expects to receive rental proceeds of approximately $60,000 in each of the next three years under this agreement.

PURCHASE COMMITMENTS The Association has entered into a purchase agree-ment with a hotel for guest rooms relating to its annual conferences. Purchases under these agree-ments are expected to approximate $531,000 and $451,000 for the years ending January 31, 2014 and 2015, respectively. Should the agreement be cancelled, The Association may be subject to can-cellation fees contingent on the ability of the rooms to be resold.

Minimum rental payments due under the leases are as follows:

NOTE 4–Pledges Receivables

JANUARY 31, 2013 2012

NOTE 5–Property and Equipment

Furniture and equipment $ 769,425 $ 746,514 Software 314,806 314,806Leasehold improvements 185,327 185,327 1,269,558 1,246,647Less accumulated ( 1,148,278) ( 1,080,764 ) depreciation and 121,280 165,883 amortization Construction in process 100,862

$ 222,142 $ 165,883

JANUARY 31, 2013 2012

NOTE 6–Commitments

YEAR ENDING JANUARY 31,

YEAR ENDING JANUARY 31,

20

As of January 31, 2013, net assets are temporarily

restricted for the following purposes:Research awards $ 6,255,022 Other programs 2,005,422 $ 8,260,444

Permanently restricted net assets includes the beneficial interests in two trusts that The Association does not administer. The investments of each trust are administered by a trustee, who is independent of The Association, and distributions are made to The Association in accordance with the trust agreement for each trust. The beneficial interests in these trusts approximated $684,000 and $657,000 at January 31, 2013 and 2012, respectively.

Permanently restricted net assets also include research endowment principal of approximately $240,000, which is held in perpetuity to generate earnings to support research expenditures.

The Association maintains a 401(k) defined contri-bution plan, which is subject to limitations set forth by the Internal Revenue Code. The plan covers all employees who meet the requirements of the plan. The total expenses relating to the plan were $189,887 and $110,755 for the years ended January 31, 2013 and 2012, respectively.

The Association uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine the fair value disclosures. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in many instances, there are no quoted market prices for The Association’s various financial instruments. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be re-alized in an immediate settlement of the instrument. The Association groups its assets and liabilities measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

The three levels of the fair value hierarchy are as follows:

• Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that The Association has the ability to access at the measurement date.

• Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

• Level 3 inputs are unobservable inputs for the asset or liability.

The level in the fair value hierarchy within which a fair measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

The following table presents assets and liabilities that are measured at fair value on a recurring basis at January 31, 2013:

ASSETSInvestments in marketable securities $ 5,197,117 2,117,170 $ 7,314,287 Beneficial interest in perpetual trusts $ 970,275 970,275 Contributions receivable from charitable remainder trusts 207,483 207,483LIABILITIES Annuity payment liability ( 788,970) ( 788,970)

$ 5,197,117 $ 2,117,170 $ 388,788 $ 7,703,075

FAIR VALUE MEASUREMENTS AT JANUARY 31, 2013 LEVEL 1 LEVEL 2 LEVEL 3 TOTAL

NOTE 7–Temporarily Restricted Net Assets

NOTE 8–Permanently Restricted Net Assets

NOTE 9–Employee Benefit Plan

NOTE 10–Fair Value Measurements

21

CORPORATE PARTNERS

$100,000+

BAYADA Home Health Care

Pride Mobility Products Corporation

Sanofi US

$25,000 – $99,999

Avanir Pharmaceuticals

Biogen Idec

ICAP Energy, LLC

Pfizer

Pharmaceutical Research and Manufacturing Association

PostNet

$5,000 – $24,999

Biotechnology Industry Organization

Kaufman, Hall & Associates, Inc.

Merck & Co., Inc.

Occidental Petroleum

Permobil

Vitas Hospice Services, LLC

Total Contributions from Corporations - $1.18 million

22

Anonymous (27)

Anonymous in memory of Bernard Johnson

Anonymous in loving memory of William J. L’Heureux

Anonymous in loving memory of Ross

Anonymous in loving memory of my father, Henry M. Unger

Ethel Adler in memory of Adam

Kent and Dara Alexander*

Marianne Allgaier in memory of Edwin Allgaier

Thomas P. Anderson, Jr.*

Dorothee P. Angel*

Anna M. Arnold in loving memory of my son, John W. Arnold

Mrs. Dorothy Austin

Mary Beth Baker in memory of my husband, Gary

Margot K. Baldwin in memory of Irene Billingham and Joseph Almirall

Erica and Robert Balint

Lester Baltimore in memory of my wife, Sue Levering

Jeff and Trina Bandelow

Maureen Barber Hill in memory of Wayne Barber, Sr.

Fanny Barnes†

Lawrence R.† and Isabel† Barnett

Marvin and Dulce Barofsky

Arthur H. Barrett†

Dorothy Barth†

Mrs. Margaret A. Beans*

Joe Ann Bearly†

Mr.† and Mrs.† Avery J. Beer*

Rick Beers*

Dr. Kirk Benson

Rhea M. Berger

Sharon T. Betzelberger*

Terry L. Betzelberger*

Christian Olav Bing

Gary L. and Elizabeth M. Bishop in loving memory of Alex McKelvey

Rolf F. Bjelland in memory of Carolyn B. Bjelland

Robert J. Bjorseth*

Ronald J. Blaney in loving memory of my mother, Rhea Blaney

Eileen Kay Blau in memory of my beloved husband, Robert W. Smith

Gary and Amy Bobo in memory of Margaret B. Peugeot

Irene P. Bolton in memory of Maureen Cantwell, sister-in-law

Doris M. Bomgardner

Carol J. Booth and Family in memory of E.G. Booth

Louis G. Booth† in loving memory of my wife, Katie

Joan S. Borowsky

Mrs. Michael W. Bowen†

Mr. and Mrs. Schuyler L. Brooks

Andrew T. Brophy

Martha† and Bert† Brown

Mady Brown in loving memory of my parents, Rose and Selwyn Cohen

Nelle H. Bruce†*

Margaret A. Bruening

Frederick and Elizabeth Burcaw in memory of Iva Burcaw and Ralph Frederick

Betty J. Burritt†*

Mr. and Mrs. Denny Burroughs in loving memory of Virginia Doty Burroughs

Margaret M. Busch† in loving memory of my granddaughter,

Stephanie Vetvick Hunting

Mrs. Meta Calise†* in memory of Vincent Joseph Calise, beloved husband and father

Cape Rider Trust in memory of Barbara Lee Schneider

John C. Carmody

Mr. John H. Carrington in memory of my brother, Dick Carrington

Mr. Robert F. Cavedo*

Jayne M. Cawthern

Doris M. Charles in honor of Richard Charles

Don G. Chatlien in loving memory of my wife, Doree M. Chatlien

Mrs. Mary Thuss Cheney† in loving memory of my mother, Gladys F. Thuss

Dr. and Mrs. Richard Chessick in loving memory of Edward FriedmanLance Christian

Michael Citra†*

Richard L. “Dick” Clark in memory of Donna Clark

Joe and Eleanor† Codomo in loving memory of our son, Robert Vincent

Selwyn S. Cohen†*

Beverly E. Collingwood in loving memory of Alfred A. Keith

Beckie and David Cooper

Christine Creed†*

Elizabeth Crossley in loving memory of my sister, Gerlinde Lindner

Will Cutspec†*

Barbara Dabul, Ph.D.* in memory of Jack Magennis

Lauren A. D’Alessandro to honor Connecticut PALS and families

Ruth S. Dann* in memory of Elliot W. Dann

The Honorable Jay Daugherty and Mrs. Lyn E. Daugherty*

Helen K. de Kanter†*

Therese Decker

Ellen Dennis

Harold and Elizabeth Dettinger in honor of Emma Dettinger

Mrs. Haroldyne Dickinson† in memory of my husband, Howard I. Dickinson

V.E.† and M.H. Dornbach, Jr.*

Charlotte S. Dutka† in memory of my husband, Len Dutka, with thanks to former patient representative Mary Lyon

Elaine Dutka in celebration of the life of my dad, Leonard Dutka

Catherine E. Easter

Alfred D. Egendorf† in memory of son Frederic

Kathleen M. Elkins, Ed.D. in loving memory of my husband, Robert J. Elkins

THE LEGACY SOCIETYThe Legacy Society was established to honor those individuals who, through their generosity of spirit, have included The ALS Association in their long-term financial and philanthropic plans. We gratefully acknowledge their commitment to our core mission of advancing critical ALS research, providing compassionate care services and increased public policy efforts in our ongoing quest for a world without ALS. * Charter Member / † Deceased

23

Peggy Ellertson in memory of my father, Thomas L. Harsell, Jr.

LaVon Elsen in loving memory of my husband, Bernie Elsen

Sheila† and Richard Essey*

Mr. and Mrs.† Glen Ethier*

Marilyn J. Fall in memory of Wayne L. Stiede

Evelyn J. Ferngold in loving memory of my mother,

Dora Broomfield Ferngold

Frank Ferrara†

Allen L. Finkelstein

Donald H. Flanders

John F.† and Mary Louise† Fogarty*

Jane Fosler† in loving memory of my husband, Keith Fosler

Ruth J. Fox†

Scott Fox in loving memory of Arthur and Vera Fox

Patricia M. Franks

Mary Kay† and John G. Fry

Howard and Jodie Furbee in celebration of the life of Velma Zeigler Folck

Floyd Gadt*

Robin R. Ganzert in memory of Michael Aheron

Eugene R. Gardiner

John H. Gauger in memory of my wife, Sandy

Nancy George in memory of my beloved husband, Ernest George

Donna Giardina in loving memory of Pam Maxwell

Marbeth W. Gibson in memory of Thomas C. Whitney, beloved brother

Jane H. Gilbert

Gillett Family Trust

Roger and Maxfalda Gleckman

Rose B. Gorin†*

Linda Gottlieb*

Cynthia A. Greene

Mrs. Jane T. Gregory†* in memory of S.L. (Paul) Gregory

The Reverend Joseph Grosko

Karla Sue Gunn and John B. Gunn*

Elizabeth A. Guon†*

Barbara M. Hadley* in memory of Charles E. Younkman

Herbert A. Hale

Stanley and Maureen Hall in memory of my mother, Helen Coulthard

Wendy L. Hall to honor my father, Ty Hall, who gave me

so much love

Terry Halpin*

Kim A. Hanna

Velma L. Hanson† in loving memory of my husband, Richard H. Hanson

William A. Harrison, Jr.* in loving memory of my life partner, Michael B. Huntley

Philip† and Joan† Hart*

Michael W. Havlicek*

Karl W. Helft in memory of Raquel P. Helft, loving wife and mother

August G. Hiebert†

Jack Hilderbrand*

Eleanor N. Hill†

Kent Hill in memory of my wife, Sandra Hill

Chuck and Mares Hirchert in loving memory of my mother, Margaret Westbrook Hirchert

David and Debra Hirschfeld in memory of Mary Elizabeth Roche

Alfred J. Hoffman†*

Emma M. Hohlfield

Mimi Holcombe in loving memory of my mother, Anne S. Cowie

Marie L. Holle in loving memory, Clayton R. Demo

Annie M. Holley

Burt Holtzman in memory of Pauline Holtzman

Ms. Sally Horner

Barbara Hummel in loving memory of Mark L. Tomchin

Wilbur Hutchins†

Floyd N. Iverson† in loving memory of my wife,Viola M. Iverson

Kimberly Johnke

Orville E. Johnson†*

Ray Jordan in loving memory of my wife, Sally A. Jordan

Mary S. Kassabian

Colonel Jacquelin J. Kelly (Retired)

James and Nancy Kenzik

Rosamond Keough in loving memory of John J. Keough

John C. Keyes†

John R. Kicklighter in memory of Vera Mae Kicklighter

Shelley King in memory of Lynn Smith of Maine

Lynn M. Klein*

Sherry and Andy Klein

Marvin† and Joan Kloehn

Cynthia Knoche

Dorothy Komarek

Shannon and Joe Komsky in loving memory of Barry Komsky

Valerie A. Konkle in memory of my sister, Barbara Konkle Kelly

Marie K. Kovacic† in memory of my daughter, Katherine Kovacic Dolley

Wilson N. Krahnke

Melanie Krebs

Ms. Andrea Krill in loving memory of my father, Peter Krill

Cindy La Montagne in loving memory of my amazing husband,

David E. La Montagne, Sr.

Mrs. Mildred N. Landecker in memory of Dr. Louis Landecker

Peter B. Landecker* in memory of Dr. Louis Landecker

Ralph LaPlant

Gordon L. Larsen

Syble Early Lashley in memory of my mother, Irene Sitton Early

Martha and Brian Law in loving memory of John Hovenden

Hazel M. Lawson†*

Gary A. Leo

Luis E. Leon in memory of Clemencia Leon

Kenneth E.† and Barbara J. Levin in memory of Gail Levin Peterzell

Louis and Jocelyn Libby

Karen K. Lienau in loving memory of my mother, Thelma C. Kahler

Thelma Lietzan†

John M. Lima in loving memory of my wife, Emma Sherratt Lima

G. Mary Lincoln in loving memory of Bob Lincoln

Margaret F. Londy† in loving memory of my sister Virginia Rashbaum

Donald R.† and Mary Lois† Long

Sherry Lougher in loving memory of my mother, Mildred Erickson Hatton

THE LEGACY SOCIETY CONT.

24

Dee Dee Lowland*

Marjorie MacClean in loving memory of Edward W. MacClean

Gloria Salerno Maehl and Gary Maehl in loving memory of Dr. Charles Salerno

Nicolas Mares† in loving memory of Delia, dear wife and mother

Barbara Martin in loving memory of my husband, Wayne O. Martin

Leonora O. Masterson

Laila Matthews

Edith Mattmiller†

John† and Denise Matuszewski

John A. Mayott†*

Jane L. McBride†*

Rosezell McCarty-Oliver in loving memory of Lawrence McCarty

Aubrey McCauley

C. Thomas McClintic and Sandra McClintic

Susan and Kevin McCormack

Ms. Susan McCray*

Laura McCrum†*

Doris L. McGowan† in loving memory of my husband, Jim

Mrs. Albert McNash in loving memory of my husband,

Albert H. McNash

Mrs. Mable Messer†*

Paul B. Micheel†* in memory of Viola

Tina and Trygve Mikkelsen in memory of Sheila Essey

Marie A. Mildram

Charles and Nancy Miller in loving memory of Stanley Drexler

Donald F. Mills in memory of my wife, Edna Bauer Mills

Mr. and Mrs. Joseph Miloscia* in loving memory and in honor of

Mrs. Patricia Ciccarello

Mrs. James S. Mims

Eileen Mittleman in loving memory of my father, Ben Mittleman

Margaret and Walter Molony

Heather and Garry Montag

Maria Montalbano

Randy Vance Morgan in honor of my mother, Mahaley Sudie Morgan

Annette and Stuart Morris

J. Kent Morrison in loving memory of my wife, Jeanne Morrison

Karen A. Moschetto in memory of my uncle, Arthur Johnson

David Moses and Lisa Roberts

Lillian Moskowitz†*

Wesley W.† and Lynne E.† Movitz

Louis Mufich in loving memory of my wife, Minerva J. Mufich

Mr. and Mrs. Larry Munoz in loving memory of my dad, Reuben Munoz, Sr.

Sherry L. Murray in memory of my husband, CDR Rick Murray, USN (Retired)

Mrs. John W. Musick in loving memory of my son, Charles Whitley Musick

Mrs. Rena L. Myrick in loving memory of my husband, F. Guilford Myrick

Evelyn Nasielski

Alice Nedelec* in loving memory of Marie A. Nedelec

Anita Nelkin† in loving memory of my husband, William Nelkin

Sonja Nelson honoring Carrie Elene Layel

Ruth Neuman†*

Anamarie Neumiller in memory of my father, Louis B. Neumiller

Gerda Newbower†

Genevieve Newton†* for Lowell Newton

Sean Newton* for Lowell Newton

Florence R. Neyer

Ken Nicholls

Rodney W. Nichols

Richard A. Nimphie in memory of Doris E. Nimphie

Earle and Catherine O’Donnell

Lynn C. O’Hara

Doris L.† and John M.† O’Hare*

Benjamin S. and Dorothy F. Ohrenstein*

Blanche J. Owens in memory of my husband, Joseph D. Owens

Elouise Pacitti† in memory of Robert, loving husband and father

Lauraine Painter†* in memory of Edwin J. Painter

Richard Palank

Thomas W. Palmer

Leighton Palmerton in memory of my wife, Ann A. Palmerton

Mrs. Harry G. Pantages

The Parsons+ Family Trust* in loving memory of Hilda Freese

Catena and Frank Passalacqua

J.R. and Margy Patterson in loving memory of Linda M. Patterson

Katherine P. Payne† in loving memory of my brother, Stuart MacMackin

Warner A. Peck †*

Andrea L. Perr in memory of my brother, Geoffrey S. Perr

Mrs. David V. Perry*

John E. Perry, Jr. in loving memory of Charlotte P. Gromberg

Mary Jo Peyton in memory of my brother, John E. Peyton, Jr.

Ellyn C. Phillips

Kathleen McGuire Pierce in loving memory of six family members with ALS

Anita M. Pollak in memory of Mervin Channing Pollak

Viola E. Porter†

Lillian B. Potts†

Ramona L. Pressley in memory of my husband, William F. Brooks;

and nieces Karen, Laura, and Susan, and nephew Brian

Rose Marie Proietti in loving memory of Mark Savory

Robin L. Quigley, Captain U.S. Navy (Retired) in honor and in memory of Joe Martin

Dean Rasmussen*

Mary Alice Reddick

Mrs. Martha N. Rees† in memory of Deacon Paul J. Rees

Bruce† and Sherrie Reid

Margaret V. Reustle in loving memory of my husband, William

Harry E. Rice, M.D.*

Kelli Richmond†

Mary C. Riggs

Mrs. Helen T. and Ms. Jennifer T. Rimerman in loving memory of Morton W. Rimerman

Carl and Becky Rizzuto in loving memory of our mom, Antoinette Carvelli

Ms. Jean M. Roldan in honor of Paulette Gasne

N. Anthony Rolfe

Juan C. Ros

Mr. Richard Rose†

Gerald† and Concetta Ross

THE LEGACY SOCIETY CONT.

2525

Richard S. Roth

Janis M. Rothermel

Jeff Rowe in memory of Frank Rowe

Richard J. Ryan†

Ronald R. Salbenblatt†

Mrs. Annette Powell Salerno in memory of Charles, beloved husband

Thomas A. Scamuffa

Carol L. Schaerer in loving memory of my sister, Robertine Massey Boyer

Robert L. Schenck*

Frances Friedman Schloss in loving memory of my late husband,

Justin Friedman

Ben F. Sears

John and Barbara Seibert

Norma M. Shearer† in loving memory of Ralf De Mouthe

Edythe B. Sheinbaum in loving memory of my husband, Milton

Judith Shelton

Mrs. Corliss Sherry my heart, my love––Clayton L. Sherry

Nancy E. Shire

Ruth Shively in loving memory of my son, Michael Shively

Marilyn Simon-Gersuk and David Gersuk

Mary Smiley in memory of my son, Steven Smiley

Elliot and Linda Smith in loving memory of my father, William Wallace Smith

Frances Virginia Smith

Merrill K.† and Hazel P.† Smith

Patricia Snyder and Family in memory of Thomas T. Snyder

Kirsten Anne Nystrom Snyder and Brandt Edward Snyder

Marion J. Solow†

Theresa Ridgway Soracco

Mr. and Mrs. Robert L. Sorenson* in memory of Wayne L. Stiede

James O. Speer†*

Dr. and Mrs. Charles J. Spengler

Laura and Sarah Stanley in memory of my mother, Sylvia R. Stanley,

and all the members of her family who have suffered from ALS

Karen Starleaf-Abounayan*

Mr.† and Mrs. Gordon F. Stewart* in memory of Jerome S. Love, M.D.

Ralph R. Stillwagon in loving memory of Eleanor Stillwagon,

dear mom

Elaine F. Stone†*

Larry Stough honoring Carrie Elene Layel

Clifford E. Strachan* in loving memory of my wife,

Helen Virginia Strachan

James and Prudy Streem Trust

Peter Strugatz*

Gregory M. Stuart a tribute to my friends who have lived with ALS

Judy Stuart in memory of my husband, Alan A. Stuart

Glenn Suhr

Ed Sukla

Pauline Sims Swain† in memory of my friend, Koziell Poklewski. He lived with ALS for 12 years.

Jerry Taylor in celebration of the life of Russell Jackson

Maybelle M. Taylor† in loving memory of Frederick A. Taylor

Steven L. Ross† and Carol L. Thacher*

Kathryn and James Thomas

Lori Tiller

John Timko

Mary Nancy Todd in loving memory of my mother, Nancy Dunn Procter

Dorothy E. Travinek in loving memory of my uncle, Michael Smiles

Judith and David† Travis

Monte Tudor-Long

Marie E. Turianski in memory of my husband, Gerald W. Turianski

Doug† and Loretta Turner

Elisabeth Twist

Mr.† and Mrs. Roy Uhlman

Mert Urness in memory of brother Gary A. Urness

Vincent G. Uttley* in celebration of the life of Michael Rice Bertschy

Nancy Van Wyhe in loving memory of my husband, Conley Van Wyhe

Mr.† and Mrs. Theodore H. Vandling

Frank C. and G. Maxine Vasek*

Rosa C. Vàsquez

Electra Venetsanos†*

Henry Vera in memory of my loving wife, Lorraine Vera

Charles H. Viens*

Ellen C. Voie

George W. Wagner*

Robert F. Wallace in memory of Marilyn Battelli, cherished wife, mother, daughter and beloved sister

Mr.† and Mrs.† Daniel J. Walsh*

Lucille J. Walter

Rev. Charles W. Ward Renee and Charles, love always/together always

C.J. Ward

Clifford W. Wauters, M.D.† in loving memory of Helen, beloved wife and mother

Sam† and Karolyn Welty*

Mr.† and Mrs.† Carlyle Whistler in loving memory of my father, Everett Garrison

Claire Whitaker in memory of my son, E.F. Wallengren

Jean G. White in memory of my beloved mother, Marie Griffin, and my loving sister, Elaine Gibler

Ken and Alma Wiegand in loving memory of Toshiko Densford

Clayton Williams

James S. Williams†

Laural Winston* in memory of Aunt Rubye and Uncle Bob Harmon

Sharon Wlosek

Mary Sylvia Wolfrey† in loving memory of my husband, Bill Wolfrey

Harriet M. Wollerstein

Victor L. Wolmer†

Agnes C. Wood†

Darlene Woodall in loving memory of my mother, Arlene Rushing Lowe

Kenneth Workman and Jennifer Workman Living Trust in memory of my beloved uncle, Gilbert Klein, D.D.S.

Katherine M. Wulf† in loving memory of my dear friend, Floyd V. Alguire

David W. Wurth

Alonzo S. Wyatt†*

Patrick M. Ziegenhorn

Mrs. Robert E. Zimmerman†

THE LEGACY SOCIETY CONT.

26

THE LAWRENCE R. BARNETT RESEARCH COUNCILThe Research Council was named in honor of Lawrence R. Barnett, founding chairman of the organization, who became affectionately known as the “grandfather” of The ALS Association for his tireless devotion to finding a cure. We are honored to recognize the distinguished members of the Lawrence R. Barnett Research Council, who are listed below. Through their commitment and generous financial support, our global research program continues its relentless pursuit of treatments and a cure for ALS. * Charter Member / † Deceased

VISIONARY$20,000 and above

Sally Akin Estate of Gary Wayne Akin

Lawrence R.† and Isabel† Barnett

Lawrence R. Barnett, Esq.

The Frankel Familyin memory of Virginia Casey Frankel and Marian Jindra

Kim and Susan Henryin memory of Elbert Henry

Bob and Beckie Kevoianin honor of Duane Parker

Robert Luongo ALS Fund, Inc.

Edmund G. McCurtain IIin memory of Edmund McCurtain

Phi Delta Theta International Fraternity’s

Iron Phi Program

Helen C. Saults†

Frances Friedman SchlossBarbara Vanderbilt Peck/Justin Friedman Fund for Neurological Research

Corinne Schwartzin memory of Dr. Joel Kleinman

The David Vickter Foundation

E.F. Wallengren Hoopfest for ALS ResearchThe E.F. Wallengren Fund for ALS Research

The Wasily Family Foundationin memory of Ms. Anne V. Wasily

INNOVATOR$10,000 to $19,999

Mr. and Mrs. Robert V. Abendroth, Esq.in memory of Lawrence R. Barnett

Mary Jean Blantonin honor and in memory of John C. Blanton

Dr. Harold and Phyllis BrourmanThe Neil Brourman, M.D. ALS Research Fund

Mr. Thomas E. Caestecker

Barbara HummelMark L. Tomchin Research Fund

Donald F. Millsin memory of my wife, Edna Bauer Mills

Ellyn C. Phillipsin loving memory of my husband, Alan, and my parents, Morton and Malvina Charlestein

The Scrivan Family FoundationThe Michel A. Scrivan Family Fund

Mr. and Mrs. James S. Whittenin honor of Mr. Steve Wilson

LEADER$5,000 to $9,999

Anonymous

Atkins School Districtin memory of Jennifer Virden-Holley

The City of Avondale Estates

Barbara and Buddy FreitagThe Neil Brourman, M.D. ALS Research Fund

Elinor M. Georgopulo

Stacey Korsin memory of Frances Kors

Pachulski, Stang, Ziehl & JonesHarry F. Davis ALS Fund

Mr. and Mrs. Robert Pokelwaldt

Ralphs Grocery CompanyThe E.F. Wallengren Fund for ALS Research

Bill Robinson

Eugene and Elizabeth H. RosenbergRosenberg Research Fund

Edward and Dana SlatkinThe Neil Brourman, M.D. ALS Research Fund

Ellen Wattin loving memory of Gordon Watt

Claire Whitakerin memory of my son, E.F. Wallengren

Robert L. Wintermyer, Ph.D., PA-C

PARTNER$1,000 to $4,999

Bruce and Janet AdlerRosenberg Research Fund

The ALS Association Minnesota/North Dakota/South Dakota Chapterin honor of Sue Spalding

Rene J. Beckham, M.D. and John J. Shufeldt, M.D.in memory of Thomas W. Beckham, Ph.D.

Lili and Jon BosseThe Neil Brourman, M.D. ALS Research Fund

Joan K. Bower-Oakland†

Mady Brownin memory of Rose B. Cohen

Dr. Spencer L. Brown and Dr. Lauren C. Pinter BrownThe Neil Brourman, M.D. ALS Research Fund

Dr. and Mrs. J. Bruijn

Fred and Elizabeth Burcawin memory of Iva Burcaw and Ralph Frederick

Charles M. and Monica A. Burkett*in memory of Charles E. Burkett

Marjorie V. Butcherin honor of Marie-Claude Minard and in memory of Christian H. Minard

Mark Calmesin honor of Jane Calmes

The Gary and Jan Campbell Family FoundationKevin and Kathleen Crittenden

27

John C. Carmody

Sharon F. ChapmanThe George Chapman ALS Research Fund, in memory of George

Cochran Family Foundation

Fred Coffield Fund for ALS

Peter and Jo CornellThe Neil Brourman, M.D. ALS Research Fund

Carleton R. Cummings, Jr.in memory of Barbara “Bobbie” Cummings

Donald Cutler

Alvin and Linda Dietz Fund

Cynthia H. Drollinger

William and Robin Eilandin memory of Billie P. Eiland

Carolyn Ford Pennington Benevolent Fund

Michal Freedman*

Mr. and Mrs. Robert A. Gay

Dr. Martin G. Giesbrechtin loving memory of Patricia Berlin

Mary Cornelia Ginn

Drew and Myra Goodman

Peter J. Hackett

Donald R. Hammonds

Joyce C. Harris

Stephen P. Hassin memory of Harriet S. Hass

Robert V. Hemm, Jr., and Linda D. Hemm

Maynard G. Hinein honor and remembrance of my dear wife, Bonnie June Hine

Hollywood Charity Horse ShowThe E.F. Wallengren Fund for ALS Research

Samuel and Hannah Holzman Trust

Edward and Marcia Horowitzin memory of Aaron Horowitz and Marjorie Horowitz Oman

Jay and Delia Jenningsin memory of Rob Marks

Laura Davis JonesHarry F. Davis ALS Fund

Janet C. Kireker

Howard B. and Susan L. Levy*in memory of Jack and Phyllis Levy

David H. Lowe, M.D.in memory of Susan Lowe

Marcia A. Luisi, M.D.in memory of Michael F. Luisi

Dr. York T. Mandra

Gary MarksThe Neil Brourman, M.D. ALS Research Fund

Clark H. McGeheein honor of Robert W. McGehee

Albert Nocciolinoin memory of Emma Nocciolino

Anamarie Neumiller

Thomas K. Ngin memory of Shan Ng

Allen J. and Lorraine Noveckin memory of Margaret Noveck

Randy and Karen O’Harein memory of Doris L. (Dee) O’Hare and Diane P. (Dee) Stone

Bernard Paiewonsky and Family*in memory of Sabina Paiewonsky

Phi Delta Theta-Idaho Alpha Chapterin memory of our brother, Lou Gehrig

Anita M. Pollakin memory of Mervin Channing Pollak

Robin L. Quigley, Captain U.S. Navy (Retired) in honor and in memory of Joe Martin

Dr. and Mrs. S. Michael Roein memory of Jack Michael Roe, M.D.

Murray Rothsteinin memory of Jacqueline S. Rothstein

Betty Scharfin memory of William Scharf

Mark A. Siem and Joan S. Siemin memory of Shirley Staton

Harry and Sandra Strainin memory of Art Doyle

Judy Stuartin memory of my husband, Alan A. Stuart

Brenda Vathauer Slade

Helen F. Weber*in memory of William C. Weber, Jr.

Michael and Nicole Weisin memory of Bernell Weis

Anne H. Winksin memory of Megan Gifford-Foulis

Woodward Family Foundation

Ken and Marie Youngbloodin memory of George J. Pitre

Mary Jane YueThe Neil Brourman, M.D. ALS Research Fund, in honor of Josie and Richard Lee, in memory of their son, Tommy D.M. Lee

THE LAWRENCE R. BARNETT RESEARCH COUNCIL CONT.

27

28

This report lists the names of individuals, corporations and foundations that made contributions to The ALS Association between February 1, 2012 and January 31, 2013. Every effort has been made to ensure the accuracy of this listing. If your name has been inadvertently omitted or listed inaccurately, please accept our apologies and contact our office at 888-949-2577.

Thank you to all of our donors who supported The ALS Association with a contribution of $1,000 or more, which are listed below:

CORPORATIONS, FOUNDATIONS AND ORGANIZATIONS

Anonymous

Advantage Testing, Inc.

Alliant Energy Foundation

Alpha Delta Pi Foundation, Inc.

Alpha Delta Pi Iota Chapter

Alpha Gamma Rho

ALS Society of Canada

America’s Charities

AquaSid, LLC

Archer Daniels Midland Co.

The Association for Frontotemporal Degeneration

ATG Rehab

Avanir Pharmaceuticals

AYCO Charitable Foundation

Aylward Family Foundation

Bank of America Foundation

Bayada Home Health Care

Edward and June Bernstein Foundation

Beth Shalom of Carroll County

Biogen Idec

Biotechnology Industry Organization

Bluco Corporation

BNY Mellon Community Partnership

Boeing Company Political Action Committee (BPAC)

Booz Allen Hamilton

PHILANTHROPY

Bristol-Myers Squibb Company

BTIG, LLC

California Community Foundation

The Capital Group Companies, Inc.

Cars 4 Causes

Charity Gift Certificates

Check Point Software Technologies, Inc.

CNA Foundation

Coles River Club

Comcast / One Comcast Center

Community Foundation of Central Illinois

Community Foundation for The National Capital Region

Community Foundation of New Jersey

Community Foundation serving Richmond and Central Virginia

Cordell Practice Management Group, LLC

Corymore Foundation

Cytokinetics, Inc.

The Alvin & Fern Davis Foundation

Robert E. Dods Family Foundation

The Dodson Foundation

Donna’s Dance....A Studio

Dynavox Systems, LLC

Electric City Running Club

Electromed, Inc.

Employee’s Community Fund of The Boeing Company

Employees of Northrop Grumman Political Action Committee

Energy & Resource Solutions

ExxonMobil Foundation

Fidelity Charitable Gift Fund

Finger Lakes Skeet League

Flame Enterprises, Inc.

H. Fort Flowers Foundation, Inc.

GE Foundation

Gilbert Unified School District No. 41

Global Impact

Google

The Barbara Vanderbilt Peck / Justin Friedman Fund for Neurological Research of the Greater Cincinnati Foundation

The David and Alan Greene Family Foundation

The Hainer Foundation

The Hurlbut-Johnson Fund

IBM Corporation

IBM Employee Services Center

ICAP Energy LLC

Iglewski Family Foundation

ING

Inner Space Constructors

Isis Pharmaceuticals, Inc.

The J2 Foundation

The Nathan P. Jacobs Foundation

Johnson & Johnson

JustGive.org

Kaufman, Hall & Associates, Inc.

Knopp Biosciences LLC

The Jack and Dorothy Kupferberg Family Foundation

LA-CO Industries, Inc.

LC Technologies, Inc./Eyegaze Systems

LD Commodities Portland LLC

Lee Brothers Inc.

Lee Mendelson Productions, Inc.

LegacyTree Foundation

Annette M. and Theodore N. Lerner Family Foundation

Lifetouch Inc.

Lozier Foundation

Macquarie Bank Foundation Limited

Martin Health System

The McIntosh Foundation

Merck Partnership for Giving

Michael Baker Corporate Foundation

Microsoft

MUSC Pharmacy School Class of 2012

National Philanthropic Trust

NCI Information Systems, Inc.

The Neeb Family Foundation

Neshaminy High School Drama Club

Network For Good

Occidental Petroleum Corporation

Olson/Kotowski, Inc.

The Oppenheim Family Fund

The Pattis Family Foundation

Pepsico Foundation

Pfizer Foundation

Pfizer Inc.

Pharmaceutical Research and Manufacturing Association

29

Phi Delta Theta––Illinois Gamma Chapter

Phi Delta Theta––Kansas Zeta Chapter

Phi Delta Theta––Maryland Alpha Chapter

Phi Delta Theta––Maryland Gamma Chapter

Phi Delta Theta––Mississippi Beta Chapter

Phi Delta Theta––Missouri Alpha Chapter

Phi Delta Theta––Ohio Beta Chapter

Phi Delta Theta––Ohio Mu Chapter

Phi Delta Theta––Oklahoma Beta Chapter

Phi Delta Theta––Oregon Beta Chapter

Phoebe Snow Foundation

Planet Green

The Platt Foundation, Inc.

The Polk County Community Foundation,Inc.

PostNet

Pride Mobility Products Corp.

Quest Diagnostics

Renaissance Charitable Foundation, Inc.

Richard Stravitz Gallery LLC

Roll Giving

The Irene Herbert Ross and Harper Grant Ross Foundation

SA Services LLC

Sanofi Aventis U.S.

Geoffrey and Susan Schmidt Foundation

Schwab Charitable Fund

The Thomas H. and Mayme P. Scott Foundation, Inc.

Sempra Employee Giving Network

Shugart Family Foundation

Fred Siegel Foundation

Silicon Valley Community Foundation

The Southern League of Professional Baseball Clubs, Inc.

Stand Aid of Iowa, Inc.

Stuart Steel Protection Corp.

Everett D. & Geneva V. Sugarbaker Foundation

Swiss Re

Synapse Biomedical Inc.

Louis F. & Mary A. Tagliatela Foundation

TechSoup Stock

Therm-Omega-Tech Inc.

Time Warner Cable

TisBest Philanthropy

TMI––The Episcopal School of Texas

Tobii Assistive Technology, Inc.

Tropham Foundation

Truist

United Jewish Foundation of Metropolitan Detroit

United Stationers Charitable Foundation

Vanguard Charitable Endowment Program

Vera Bradley

The Vermont Community Foundation

Visa Givingstation

Vitas Hospice Services, LLC

VMware Foundation

The Edgar V. Weir Family Foundation

Westampton Education Association

The Harold Wetterberg Foundation

Wittenberg University

Worcester Academy

ZBI Employee Allocated Gift Fund

INDIVIDUALS† Deceased

Anonymous (2)

Thomas W. Abendroth and Terri L. Mascherin

Carolyn F. Adelsten

Leah Alfonso

Dawn M. Algrim

Rene Alkoff

Chad and Sami Amosson

Dorothee P. Angel

Andrew J. Ashton

Barbara R. Ball

Jennifer Ballance

Ottis Ballenger

Lester Baltimore

Lawrence R.† and Isabel† Barnett

Lawrence R. Barnett

H. R. and Doreen Barr

Deborah Bass

Michael Batnick

Sharon D. Bell

Nancy Berkovitz

Josh M. Berman

Jay and Pamela Bieber

Michael Bisceglia

Cristina Bita

Robert J. Bjorseth

Gene and Danell Bleymaier

C. James and Carole Bluhm

Brett Boege

Brion Brandes

David G. Brandt

Robert Brooks

Tracy L. Brooks-Szegda

Heather A. Brown and Matt Brown

Karen S. Brown

Robert H. Brown, Jr. and Elaine Beilin

Chris W. Brussalis

Mrs. J. Mahlon Buck, Jr.

PHILANTHROPY CONT.

Michael Buratti

William and Janene Burke

Samuel Burton

Steve Byrd

Matthew T. Caddell

Michele Capps

Emanuel and Joan Carreras

Charles and Michele Carroll

Margaret A. Carver

Richard Chadakoff

Ann M. Chioles

Harris Chung

Joseph Cipriano

Donald K. Clark

Scott Cohen

Stephen and Nancy Cohen

Paul Colasanti

James and Margaret Coleman

John and Janet Collins

Terrie D. Combs

Chris and Janice Commons

Gary J. Connell

Will Conniff

Cathy Z. Cordisco-Emanuelson

Richard and Bunny Corey

Joseph and Sandra Corish

J.R. and Mitzie Craddock

Nancy Crockett

Neil and Mary Joe Crosby

Lisa Cuff

John and Deirdre Dabney

Elizabeth Daitch

Stephen and Lisa D’Amato

30

Michael and Patricia D’Arcangelo

William F. Darling

Susan Darrington and Bill Darrington

The Honorable Jay Daugherty and Mrs. Lyn E. Daugherty

Nancy G. Daunton

Elizabeth L. Davis

Sydney K. Davis

Daniel de Grandpre

David E. Decosse

Larned L. Delano

Jesse D. Dickson

Rudolph and Teresa Dieguez

Julie Diffenbach

Teresa Donahue

Cynthia Douthat

Dana Dratch and Esther E. Bloustein

Edward G. Eberl

Catherine Eckbreth

Mitchell and Lisa Eisen

Marianne Elam

Morton T. Eldridge

Robin M. Elliott and Thomas Craney

David Ellis

Ernest and Mary Ellison

Michael and Phyllis Elpern

Laura R. Enzbrenner

Kenneth J. Erickson

Allison Evans

Frank L. Faist and Family

Laura Felzer

Laura Finical

Robert First

Bernadine Flickinger

Mark M. Foster and Nancy K. Koehler

Michael R. Foster

Richard and Lynn Frankel

Mark and Aileen Friedlein

Betty J. Fritz

Cynthia Garretson

Jack Gendzel

E. Norman and Suzanne George

Michael and Alecia Gersh

Jane H. Gilbert

Tim Glocker

Larry C. Glotfelty and Tracy L. Glotfelty

Roberta Goin

Earl and Aya Goldberg

Martin and Sandra Goldstein

Stan Goldstein

R.C. and Connie Gonzalez

Russell and Kathy Gottfried

Anthony Grande

Mr. and Mrs. William T. Hammond

George and Kathleen Hardart

Edwin and Linda Hartz

Mr. and Mrs. Pierre D. Hayward

Edith S. Heckman†

Robert J. Hemmig

Mr. and Mrs. Donald Herman, from the John & Rose Herman Support Foundation

Donald and Bluma Herman

Susan E. Hermann

Joyce A. Hill

Lawrence and Margaret Hinders

Sherman and Pamela Hixson

Betty Hoffman

Matthew and Cindy Hogge

Wayne Hoovestol

Doris Horner

Kevin and Patricia Houlihan

Michael J. Howes

Eric W. Hoyt

Joe B. Hudgens

Kenji Iijima

Mark and Jane Ivanick

Brendan Jacksits

James A. Jahna, Jr.

Jeff Jones

Linda Joost

Judy A. Jorge

Andrew and Elizabeth Jurgenson

Bill Jurney

Susan Kaiser

George Karnoutsos

Roy Kaufmann

Dan and Nancy Kennedy

Dan and Margie Kernen

Richard and Gloria Kerns

Mary A. Kim

Franklin and Collette Kitto

Sapna Kochuparambil

Edgar and Eileen Koerner

Matthew B. Koll

Viola Kranenberg

Bryce Kranzthor and Nancy Griffin

Joanne Kranzthor

John Kugler

Joseph and Nancy Kunkel

Charles Lamont

Paul Lang

Norma L. Laubhan

Douglas Lavallee

Virginia Leitch

Gary A. Leo

Richard E. Leonardon

Jeffrey and Joyce Levine

Ben Lewis

Steve J. Lindo

Gary and Judy Lohmeyer

Cristina Lombardo

Joanne Lotreck

Joan B. Loving

Larry L. Luing

Theodore D. Lynch/The Lynch Charitable Fund

Mary Lyon

Leslie MacNeil

Gloria Salerno Maehl and Gary Maehl

Kimberly Maginnis

Heidi Magner

Eric Maier

Richard Maizel

Wendy Manning

Kate Mansergh

Todd and Felice Marcy

Maura Marczewski

Thomas L. Martin

Mrs. Russell (Marjorie J.) McChesney

Richard and Francesca McCleary

Janet M. McClelland

Christopher and Jeanne McCoy

Daniel McDermott

Linda D. McFarland

PHILANTHROPY CONT.

31

Richard and Beth McLaughry

Marney Mesch

Greg Miller

Peter Miller

Nedra R. Mise

Jose Moreno

John and Margaret Morgan

Allison Muentener

Louis Mufich

Ruth Murphy

James and Kandice Murray

Sean Murray

Thomas E. Myers

John and Michelle Neeb

Michael Newman

Terence Nicol

Albert I. Niemeyer

Alice Noll

Stuart and Marcia Obermann

Philip and Laureen O’Larey

David and Jamie Oliver

Gary Olsen

Daniel J. O’Neill

Timothy O’Toole

Thomas W. Palmer

Martha M. Parke/The Parke Charitable Fund

Stephen Parr

Jeff and Mary Patton

Mr. and Mrs. Gordon R. Pellerin

Joseph Robert Portmann III/The Portmann Family Charitable Fund

Howard S. Potter, Jr.

Gregg S. Powell

Rose Marie Proietti

PHILANTHROPY CONT.

Tanya Quinn

Nasrin F. Rahatzad

Bill and Angela Ramey

JoAnn Ranck

Sedell G. Rand

Dale and Carol Rasmusson

Chris Rath

Jim Ream

Tony N. Redd

Nancy L. Reinen

Kathy Reynolds

Michael and Anne Rhoads

Timothy and Barbara Riazzi

Shane and Robin Robison

Bobbiedine Rodda

Parker O. Roe

Nancy D. Rosan

Carol Rosenberg

Eugene and Elizabeth H. Rosenberg

John and Barbara Rothhaar

Murray Rothstein

Sharon M. Rowlen and Craig Rowlen

Richard C. Ruggeri

Thomas R. Ryan

Paul Ryken

Robert Rynalski

Nelson Saiers

Dan and Sara Sapadin

John and Dorothee Sargent

Patricia P. Savage

Michael Saxon

Thomas P. Scanlan

Gwyneth M. Schultz

Mark B. Schupack

Esther K. Schwartz

Mildred Schwartz

Neil F. Schwartz

Robert and Elizabeth Scott

Michael and Renita Seldowitz

Tracy and Helen Selmon

Mark Shacket

Lisa Sharp

Victor and Liliana Shen

Jason R. Shonk and Jennifer Randle

Mark Siebert

Samantha Siegel

Howard and Robyn Silk

Michael and Abbey Silver

Donnie and Jacquelyn Silverman

William Peter Sipe and Joyce Sipe

Jerry Skinner and Ann Cody

Lee and Cynthia Small

Gene Smith

Kevin and Laurel Smith

Edgar and Saundra Snyder

Andrew and Jane Soffel

William Soffel

Michael R. Spell

Robert and Sylvia St. Jean

Keith and Vickie Stamler

Rudolph Steiner

Diane F. Stephens

Barry Strugatz

Jan H. Suwinski and Susan Suwinski

Rebecca C. Swan

Lara Swenson

Joseph and Ellen Tessitore

Quinn Thompson

Ann E. Titzer

Allan J. Tobin

Joseph and Toshiko Tompkins

Stephen and Lawson Travers

William and Jeanne Tyler

Rhonda J. Uhlenbrock

Blanche Underwood

Elsie M. Upchurch

Robert Van Iten

Robert C. Verrett

Larry and Marianne Waggoner

Ira J. Wagner

William and Peggy Wainscott

Natalie and Larry Wassong Charitable Fund

Douglass S. Watson

John R. Wendel

Frederic Westendorf

Paul and Erika White

Jeffrey and Jennifer Whitehorn

Bernd and Frances Wiehn

Terry and Colleen Wilkins

Sabin Willett and Marta Willett

Timothy Wilson

Linda W. Windsor

Fredrick M. Wiste

Susan Wood

Gilbert D. Woolridge

Deborah Woodward

Frances F. Wurlitzer

David M. Yocum

David Zaunbrecher

Dean A. Zerbe

32

Lawrence R. BarnettThe ALS Association Chairman Emeritus

The Hon. Jay Daugherty*The ALS Association ChairmanShaffer Lombardo ShurinKansas City, Missouri

William Thoet*The ALS Association Vice-ChairmanSenior Vice PresidentBooz Allen HamiltonHerndon, Virginia

Luis Leon*The ALS Association TreasurerRetired Chief Executive OfficerRoyal Caribbean Cruises, Ltd.Miami, Florida

Douglas Butcher*The ALS Association SecretaryCBRE/LouisvilleLouisville, Kentucky

Lawrence R. Barnett, Esq.*Gipson, Hoffman & PancioneLos Angeles, California

Phyllis R. Brourman, Esq.Beverly Hills, California

Chris BrussalisPresident and CEOThe Hill Group, Inc.Carnegie, Pennsylvania

Daniel deGrandpreChief Executive Officerdealnews.comMadison, Alabama

Cynthia D. Douthat*Atlanta, Georgia

Robin R. Ganzert, Ph.D.PresidentAmerican Humane AssociationWashington, D.C.

Wilson N. Krahnke*Chevy Chase, Maryland

Edmund G. McCurtain, II*Boulder Creek, California

Kim Ann Mink, Ph.D.Global General Manager, ElastomersDow Chemical CompanyMidland, Michigan

Timothy O’TooleChief Executive OfficerVitas Healthcare CorporationMiami, Florida

Ellyn C. Phillips*ChairThe ALS Association Greater Philadelphia ChapterAmbler, Pennsylvania

Jonathan RobertsExecutive Vice President and Chief Operating Officer CVS CaremarkLincoln, Rhode Island

Elizabeth Heller Rosenberg*DirectorHaworth LibraryNew York, New York

William D. Soffel*PresidentVacation Properties Realty, Inc.Chautauqua, New York

Chris StevensVice President Corporate Relations and Customer DevelopmentKeurig, Inc.Wellesley, Massachusetts

Allan Tobin, Ph.D.CHDI Foundation Los Angeles, California

*Executive Committee MembersTRUSTEES

LEADERSHIP

3333

CHAIRMAN’S COUNCIL

Robert V. Abendroth, Esq.Whyte Hirschboeck Dudek S.C.Milwaukee, Wisconsin

Robert J. BjorsethTech Inc.Lenexa, Kansas

Andrew T. BrophyBrophy Properties, Inc.Washington, D.C.

Richard P. EsseyChairmanTemPositionsSan Francisco, California

Allen L. Finkelstein, Esq.Pavia & HarcourtNew York, New York

Alan R. GriffithCentreville, Maryland

William G. MatthewsRetired Vice President Sales3MSt. Paul, Minnesota

Benjamin S. Ohrenstein, Esq., CPAHaverford, Pennsylvania

Lawrence A. RandSenior Vice PresidentKekst and CompanyNew York, New York

Howard B. Safenowitz, Esq.Calabasas, California

Stephen H. SaltzmanNorth Bergen, New Jersey

Kenneth Wiegand, Jr.Retired Senior Vice PresidentBooz Allen HamiltonHerndon, Virginia

Laural WinstonRetired Chief Financial OfficerTECHMER PMPalm Desert, California

LEADERSHIP CONT.

34

NATIONAL OFFICE EXECUTIVE STAFF

Jane H. GilbertPresident and Chief Executive Officer

Dan ReznikovChief Financial Officer

Stevan GibsonChief Public Policy Officer

Michelle KeeganChief Development Officer

Kimberly MaginnisChief Care Services Officer

Carrie Martin-MunkChief Communications and Marketing Officer

Ken Nicholls / Lance SlaughterChief Chapter Relations Officers

Lucie Bruijn, Ph.D.Chief Scientist

LEADERSHIP CONT.

35

1275 K Street NW

Suite 250

Washington DC 20005

Phone 202 407 8580

THE ALS ASSOCIATION alsa.org